Breaking News
Get 40% Off 0
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks
Close

Livzon Pharmaceutical Group Inc (1513)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
26.25 -0.10    -0.38%
26/04 - Closed. Currency in HKD ( Disclaimer )
Type:  Equity
Market:  Hong Kong
ISIN:  CNE100001QV5 
  • Volume: 523,494
  • Bid/Ask: 26.20 / 26.25
  • Day's Range: 26.10 - 26.80
Livzon Pharma 26.25 -0.10 -0.38%

1513 Balance Sheet

 
Featured here, the Balance Sheet for Livzon Pharmaceutical Group Inc, which summarizes the company's financial position including assets, liabilities and shareholder equity for each of the latest 4 period ending dates (either quarterly or annually).
AnnualQuarterly
InvestingPro Advanced Balance Sheet
Period Ending: 2024
31/03
2023
31/12
2023
30/09
2023
30/06
Total Current Assets 17178.22 17266.17 16984.39 17927.14
Cash and Short Term Investments 11231 11407.52 10429.3 10927.85
Cash - - - -
Cash & Equivalents 11143.15 11325.72 10356.12 10837.29
Short Term Investments - - - -
Total Receivables, Net 3651.3 3626.9 4043.91 4365.45
Accounts Receivables - Trade, Net 3605.35 3574.99 3996.08 4278.52
Total Inventory 2015.39 2060.65 2142.48 2258.26
Prepaid Expenses - - - -
Other Current Assets, Total 280.53 171.11 368.7 375.58
Total Assets 25189.7 25044.83 24799.96 25726.13
Property/Plant/Equipment, Total - Net 4599.48 4565.64 4667.66 4588.49
Property/Plant/Equipment, Total - Gross - 8638.21 - 8481.55
Accumulated Depreciation, Total - -4072.57 - -3893.06
Goodwill, Net 124.91 124.91 124.91 124.91
Intangibles, Net 418.3 426.28 433.7 507.04
Long Term Investments 1665.77 1670.1 1679.76 1716.52
Note Receivable - Long Term 45.95 51.91 47.82 86.93
Other Long Term Assets, Total 407.75 221.17 199.19 183.03
Other Assets, Total -472.25 -542.8 -749.19 -962.06
Total Current Liabilities 8329.92 8087.14 7300.89 8238.88
Accounts Payable 1784.37 1658.41 1800.9 1919.52
Payable/Accrued - - - -
Accrued Expenses 187.58 3294.96 296.21 2401.66
Notes Payable/Short Term Debt 1360.01 1860.01 1560.01 1610
Current Port. of LT Debt/Capital Leases 1339.86 659.68 13.65 14.78
Other Current liabilities, Total 3658.09 614.07 3630.13 2292.92
Total Liabilities 9750.19 10278.12 10331.73 11476.3
Total Long Term Debt 864.4 1621.8 2437.71 2632.88
Long Term Debt 856.67 1612.77 2428.73 2622.26
Capital Lease Obligations 7.73 9.03 8.98 10.61
Deferred Income Tax 202.5 209.81 194.16 193.42
Minority Interest 833.34 724.21 825.8 836.44
Other Liabilities, Total -3199.98 -6345.1 -6219.1 -6267.58
Total Equity 15439.5 14766.7 14468.24 14249.83
Redeemable Preferred Stock, Total - - - -
Preferred Stock - Non Redeemable, Net - - - -
Common Stock, Total 926.64 923.94 935.55 935.55
Additional Paid-In Capital - 1029.95 1676.76 1658.51
Retained Earnings (Accumulated Deficit) 12260.81 11652.99 11300.84 10833.86
Treasury Stock - Common -128.43 - -402.09 -198.6
ESOP Debt Guarantee - - - -
Unrealized Gain (Loss) - - - -
Other Equity, Total 2380.48 1159.83 957.17 1020.51
Total Liabilities & Shareholders' Equity 25189.7 25044.83 24799.96 25726.13
Total Common Shares Outstanding 307.35 309.83 309.83 309.83
Total Preferred Shares Outstanding - - - -
* In Millions of CNY (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on the balance sheet, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

1513 Comments

Write your thoughts about Livzon Pharmaceutical Group Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
JAME Megueni
VRAQ Dec 16, 2021 10:12PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
M Stanley Downgrades LIVZON PHARMA to Underweight with TP Cut to $22.55
JAME Megueni
VRAQ Dec 05, 2021 8:32PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
LIVZON PHARMA's Key Product Still Included in New Medical Insurance Catalogue
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email